Key result
Olanzapine linked to severe neuroleptic malignant syndrome requiring intubation in a multiple sclerosis patient.
Case Report (n=1)
This case highlights the importance of recognizing and treating neuroleptic malignant syndrome in patients receiving anti-psychotics.
Heightens vigilance for neuroleptic malignant syndrome with antipsychotics in multiple sclerosis; single case leaves open causality and prevalence.
Suspicion of neuroleptic malignant syndrome (NMS) is a frequent cause of emergent psychiatric consultation. Despite early recognition, NMS has remained a syndrome that causes high rates of morbidity and mortality. A 25-year-old male with multiple sclerosis presented to the accident and emergency department and E with ataxia. He was started on steroids. On the third day, he became tearful and anxious. A diagnosis of multiple sclerosis-induced psychosis was made and he was started on olanzepine 2.5 mg BD. On the sixth day the patient was tachypneic and had tachycardia. Temperature recorded in the axilla was 45°C. Patient was intubated and electively ventilated. A diagnosis of NMS was made and treated accordingly. This case report highlights the importance of recognizing and treating NMS in a patient on anti-psychotics.
No takes yet. Share an insight, caveat, or question.
Hanumanthaiah et al. (2014) conducted a case report in Neuroleptic malignant syndrome (n=1). Olanzepine was evaluated on Development of neuroleptic malignant syndrome. Olanzepine administration in a 25-year-old male with multiple sclerosis resulted in the development of severe neuroleptic malignant syndrome requiring intubation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: